Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ginger D Constantine

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Menopause (New York, N.Y.)|December 10, 2015
Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy surveyJoAnn V Pinkerton, Ginger D Constantine
Current Opinion in Pharmacology|December 4, 2003
Estrogens in postmenopausal women: recent insightsGinger D Constantine, James H Pickar
Menopause (New York, N.Y.)|April 6, 2016
Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal womenGinger D Constantine, Risa Kagan, Paul D Miller
Menopause (New York, N.Y.)|July 1, 2014
Endometrial safety of ospemifene: results of the phase 2/3 clinical development programGinger D Constantine, Steven R Goldstein, David F Archer
Contraception|December 13, 2006
Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro gJulia V Johnson, Gary S Grubb, Ginger D Constantine
Menopause (New York, N.Y.)|December 4, 2019
Systemic estradiol levels with low-dose vaginal estrogensRichard J Santen, Sebastian Mirkin, Brian Bernick, et al.
Journal of Women'S Health (2002)|November 29, 2018
Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk FactorsGinger D Constantine, Grant Kessler, Shelli Graham, et al.
Menopause (New York, N.Y.)|August 31, 2016
Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trialGary Hattersley, Alan G Harris, James A Simon, et al.
Menopause (New York, N.Y.)|February 4, 2011
Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trialGloria Bachmann, Uel Crosby, Robert A Feldman, et al.
Menopause (New York, N.Y.)|September 21, 2016
Prescribing of FDA-approved and compounded hormone therapy differs by specialtyGinger D Constantine, David F Archer, Shelli Graham, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Menopause (New York, N.Y.)|December 10, 2015
Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy surveyJoAnn V Pinkerton, Ginger D Constantine
Current Opinion in Pharmacology|December 4, 2003
Estrogens in postmenopausal women: recent insightsGinger D Constantine, James H Pickar
Menopause (New York, N.Y.)|April 6, 2016
Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal womenGinger D Constantine, Risa Kagan, Paul D Miller
Menopause (New York, N.Y.)|July 1, 2014
Endometrial safety of ospemifene: results of the phase 2/3 clinical development programGinger D Constantine, Steven R Goldstein, David F Archer
Contraception|December 13, 2006
Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro gJulia V Johnson, Gary S Grubb, Ginger D Constantine
Menopause (New York, N.Y.)|December 4, 2019
Systemic estradiol levels with low-dose vaginal estrogensRichard J Santen, Sebastian Mirkin, Brian Bernick, et al.
Journal of Women'S Health (2002)|November 29, 2018
Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk FactorsGinger D Constantine, Grant Kessler, Shelli Graham, et al.
Menopause (New York, N.Y.)|August 31, 2016
Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trialGary Hattersley, Alan G Harris, James A Simon, et al.
Menopause (New York, N.Y.)|February 4, 2011
Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trialGloria Bachmann, Uel Crosby, Robert A Feldman, et al.
Menopause (New York, N.Y.)|September 21, 2016
Prescribing of FDA-approved and compounded hormone therapy differs by specialtyGinger D Constantine, David F Archer, Shelli Graham, et al.
Pageof 5